Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
2000 1
2001 1
2007 1
2009 2
2010 1
2011 2
2012 4
2013 5
2014 8
2015 3
2016 1
2017 6
2018 6
2019 3
2020 4
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

47 results
Results by year
Filters applied: . Clear all
Page 1
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D'Aveni-Piney M, Obéric L, Bodet-Milin C, Bories P, Olivier P, Lafon I, Berriolo-Riedinger A, Galli E, Bernard S, Rubio MT, Bossard C, Meignin V, Merlet P, Feugier P, Le Gouill S, Ysebaert L, Casasnovas O, Meignan M, Chevret S, Thieblemont C. Vercellino L, et al. Among authors: berriolo riedinger a. Blood Adv. 2020 Nov 24;4(22):5607-5615. doi: 10.1182/bloodadvances.2020003001. Blood Adv. 2020. PMID: 33180899 Free PMC article.
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.
Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac AC, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Delarue R, Farhat H, Quittet P, Berriolo-Riedinger A, Tempescul A, Edeline V, Maisonneuve H, Fornecker LM, Lamy T, Delmer A, Dartigues P, Martin L, André M, Mounier N, Traverse-Glehen A, Meignan M. Casasnovas RO, et al. Among authors: berriolo riedinger a. Lancet Oncol. 2019 Feb;20(2):202-215. doi: 10.1016/S1470-2045(18)30784-8. Epub 2019 Jan 15. Lancet Oncol. 2019. PMID: 30658935 Clinical Trial.
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.
Le Gouill S, Ghesquières H, Oberic L, Morschhauser F, Tilly H, Ribrag V, Lamy T, Thieblemont C, Maisonneuve H, Gressin R, Bouhabdallah K, Haioun C, Damaj G, Fornecker L, Bouhabdallah R, Feugier P, Sibon D, Cartron G, Bonnet C, André M, Chartier L, Ruminy P, Kraeber-Bodéré F, Bodet-Milin C, Berriolo-Riedinger A, Brière J, Jais JP, Molina TJ, Itti E, Casasnovas RO. Le Gouill S, et al. Among authors: berriolo riedinger a. Blood. 2021 Apr 29;137(17):2307-2320. doi: 10.1182/blood.2020008750. Blood. 2021. PMID: 33211799 Free article.
PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma - Authors' reply.
Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Berriolo-Riedinger A, Fornecker LM, André M, Meignan M. Casasnovas RO, et al. Among authors: berriolo riedinger a. Lancet Oncol. 2019 Apr;20(4):e190. doi: 10.1016/S1470-2045(19)30156-1. Lancet Oncol. 2019. PMID: 30942177 No abstract available.
Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study.
Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Du FL, Dupré PF, Bachelot T, Gabelle P, Chauvet MP, Coeffic D, Barbe C, Prevost JB, Paintaud G, Thibault G, Ferhat A, Dupin J, Berriolo-Riedinger A, Arnould L. Coudert B, et al. Among authors: berriolo riedinger a. EClinicalMedicine. 2020 Nov 4;28:100566. doi: 10.1016/j.eclinm.2020.100566. eCollection 2020 Nov. EClinicalMedicine. 2020. PMID: 33205032 Free PMC article.
Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network.
Blanc-Durand P, Jégou S, Kanoun S, Berriolo-Riedinger A, Bodet-Milin C, Kraeber-Bodéré F, Carlier T, Le Gouill S, Casasnovas RO, Meignan M, Itti E. Blanc-Durand P, et al. Among authors: berriolo riedinger a. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1362-1370. doi: 10.1007/s00259-020-05080-7. Epub 2020 Oct 24. Eur J Nucl Med Mol Imaging. 2021. PMID: 33097974
Role of FDG PET-CT in the treatment management of Hodgkin lymphoma.
Berriolo-Riedinger A, Becker S, Casasnovas O, Vander Borght T, Édeline V. Berriolo-Riedinger A, et al. Cancer Radiother. 2018 Sep;22(5):393-400. doi: 10.1016/j.canrad.2018.06.001. Epub 2018 Jul 20. Cancer Radiother. 2018. PMID: 30033076 Review.
Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project.
Bailly C, Carlier T, Berriolo-Riedinger A, Casasnovas O, Gyan E, Meignan M, Moreau A, Burroni B, Djaileb L, Gressin R, Devillers A, Lamy T, Thieblemont C, Hermine O, Kraeber-Bodéré F, Le Gouill S, Bodet-Milin C. Bailly C, et al. Among authors: berriolo riedinger a. Haematologica. 2020 Jan;105(1):e33-e36. doi: 10.3324/haematol.2019.223016. Epub 2019 Aug 1. Haematologica. 2020. PMID: 31371411 Free PMC article. No abstract available.
Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma.
Kanoun S, Rossi C, Berriolo-Riedinger A, Dygai-Cochet I, Cochet A, Humbert O, Toubeau M, Ferrant E, Brunotte F, Casasnovas RO. Kanoun S, et al. Among authors: berriolo riedinger a. Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1735-43. doi: 10.1007/s00259-014-2783-x. Epub 2014 May 9. Eur J Nucl Med Mol Imaging. 2014. PMID: 24811577
47 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page